Stoke Therapeutics (NASDAQ:STOK) PT Raised to $22.00 at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK) had its price target lifted by stock analysts at Needham & Company LLC from $14.00 to $22.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 55.26% from the company’s current price.

STOK has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday. Canaccord Genuity Group increased their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.63.

Stoke Therapeutics Stock Up 37.7 %

Shares of STOK opened at $14.17 on Tuesday. The company has a market cap of $632.69 million, a PE ratio of -5.98 and a beta of 0.68. The business has a fifty day moving average of $5.88 and a 200 day moving average of $4.95. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40.

Insider Activity

In other news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $5.74, for a total transaction of $57,400.00. Following the transaction, the insider now owns 16,981 shares in the company, valued at $97,470.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $5.74, for a total value of $57,400.00. Following the completion of the transaction, the insider now owns 16,981 shares in the company, valued at approximately $97,470.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,615 shares of company stock worth $212,852. Company insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ensign Peak Advisors Inc purchased a new position in Stoke Therapeutics in the first quarter valued at about $25,000. Point72 Hong Kong Ltd purchased a new position in Stoke Therapeutics in the first quarter valued at about $27,000. Great West Life Assurance Co. Can grew its stake in Stoke Therapeutics by 46.7% in the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares during the last quarter. Dorsey & Whitney Trust CO LLC purchased a new position in Stoke Therapeutics in the third quarter valued at about $43,000. Finally, UBS Group AG acquired a new stake in Stoke Therapeutics in the third quarter worth about $47,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.